Endogenous anticoagulant therapy for sepsis: Success and failure;Gerinnungsaktive substanzen als sepsistherapeutika: Erfolg und misserfolg

Internist

Volumn 48, Issue 5, 2007, Pages 537-544

  Wiedermann, C J ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Abteilung für Innere Medizin   (Italy)

Author keywords

Antithrombin; Drotrecogin alfa; Sepsis; Therapy; Tifacogin

Indexed keywords

ANTITHROMBIN; DROTRECOGIN; HEPARIN; PLACEBO; PROTEIN C; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; HUMAN; SEPSIS; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTI-INFECTIVE AGENTS; ANTITHROMBINS; CHILD; CLINICAL TRIALS, PHASE III; FIBRINOLYTIC AGENTS; HUMANS; PROTEIN C; PROTEINS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; RESEARCH DESIGN; SHOCK, SEPTIC; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 34248371190     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-007-1840-y     Document Type: Article

References (39)

1. Abraham E, Reinhart K, Svoboda P et al. (2001) Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 29: 2081-2089
2. Abraham E, Reinhart K, Opal S et al. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290: 238-247
3. Wiedermann CJ, Kaneider NC (2006) A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis 17: 521-526
4. Baudo F, Caimi TM, Cataldo F de et al. (1998) Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 24: 336-442
5. Warren BL, Eid A, Singer P et al. (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286: 1869-1878
6. Hoffmann JN, Wiedermann CJ, Juers M et al. (2006) Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 95: 850-856
7. Wiedermann CJ (2004) Improvement in coagulation markers with antithrombin - beneficial in severe sepsis? Crit Care Med 32: 1968-1969
8. Wiedermann CJ, Kaneider NC (2004) Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis. Ann Med 36: 194-203
9. Wiedermann CJ (2006) Clinical review: Molecular mechanisms underlying the role of antithrombin in sepsis. Crit Care 10: 209
10. Wiedermann CJ, Hoffmann JN, Juers M et al. (2006) High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 34: 285-292
11. Kienast J, Juers M, Wiedermann CJ et al. (2006) Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4: 90-97
12. Rivard GE, David M, Farrell C et al. (1995) Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 126: 646-652
13. Bernard GR, Vincent JL, Laterre PF et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709
14. Eichacker PQ, Natanson C (2003) Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labelling restrictions and the need for phase IV trials. Crit Care Med 31: S94-S96
15. Vincent JL, Bernard GR, Beale R et al. (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33: 2266-2277
16. Bernard GR, Margolis BD, Shanies HM et al. (2004) Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 125: 2206-2216
17. Dellinger RP, Carlet JM, Masur H et al. (2004) Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 30: 536-555
18. Wiedermann CJ (2005) Bioethics, the Surviving Sepsis Campaign, and the industry. Wien Klin Wochenschr 117: 442-444
19. Eichacker PQ, Natanson C, Danner RL (2006) Surviving sepsis-practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 355: 1640-1642
20. Abraham E, Laterre PF, Garg R et al. (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353: 1332-1341
21. Kerr M (2006) Drotrecogin alfa does not improve outcome in children with sepsis. http://www.medscape.com/viewarticle/521400?src=mp
22. Committee for Proprietary Medicinal Products - CPMP (2001) Points to consider on application with 1. meta-analyses; 2. one pivotal study. Document CPMP/EWP/2330/99. EMEA, London, 31 May
23. Committee for Medicinal Products for Human use - CHMP (2006) Guideline on clinical investigation of medicinal products for the treatment of sepsis. http://www.emea.europa.eu/pdfs/human/ewp/471303en.pdf
24. United States Food and Drug Administration Anti-Infective Drugs Advisory Committee (2001) Drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] Xigris, bla 125029/0. FDA briefing information. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1.htm
25. Deans KJ, Minneci PC, Banks SM et al. (2004) Substantiating the concerns about recombinant human activated protein C use in sepsis. Crit Care Med 32: 2542-2543
26. Banks SM, Gerstenberger E, Eichacker PQ et al. (2003) Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question. Crit Care Med 31: 308-309
27. Warren HS, Suffredini AF, Eichacker PQ et al. (2002) Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 347: 1027-1030
28. Deans KJ, Minneci PC, Eichacker PQ et al. (2004) The efficacy of drotrecogin alfa depends on severity of illness. Crit Care Med 32: 2347
29. Committee for Medicinal Products for Human use - CHMP (2002) Points to consider on multiplicity issues in clinical trials. Document CPMP/EWP/908/99. EMEA, London, 19 September
30. Committee for Medicinal Products for Human use - CHMP (2002) Xigris european public assessment report. Scientific discussion. EMEA, London, 22 August, http://www.emea.europa.eu/humandocs/Humans/EPAR/xigris/Xigris.htm
31. Committee for Medicinal Products for Human use - CHMP (2006) Procedural steps taken and scientific information after the authorisation. Changes made after 01/10/2004. Xigris-H-C-396-S-13 x Scientific Discussion. http://www.emea.europa.eu/humandocs/Humans/EPAR/xigris/Xigris.htm
32. Anti-infective Drug Advisory Committee (2001) Anti-infective transcript of Anti-infective Drug Advisory Committee meeting, 16 October 2001. http://www.fda.gov/ohrms/dockets/ac/cder01.htm
33. AIFA (2005) Monitoraggio dell'uso del farmaco Drotrecogin alpha (attivato) - XIGRIS® nelle Terapie Intensive italiane. Bollettino d'informazione sui farmaci 1: 7-12
34. AIFA (2006) Monitoraggio dell'uso di Xigris® nelle Terapie Intensive italiane. Risultati della seconda fase di raccolta dati. Bollettino d'informazione sui farmaci 13: 70-75
35. Wiedermann CJ, Keinecke HO, Jurs M et al. (2006) Baseline severity of sepsis in subjects of the PROWESS and the Kybersept clinical trials on endogenous anticoagulants. Shock 25: 657-658
36. Wiedermann CJ, Kaneider NC (2005) A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis. BMC Emerg Med 5: 7
37. Eichacker PQ, Danner RL, Suffredini AF et al. (2005) Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial. Crit Care Med 33: 2426-2428
38. Mackenzie AF (2005) Activated protein C: do more survive? Intensive Care Med 31: 1624-1626
39. Wiedermann CJ (2006) When a single pivotal trial should not be enough - the case of drotrecoginalfa (activated). Intensive Care Med 32: 604